MTEXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
MANNATECH INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.74+1.62 (+22.67%)
Close on Oct 19, 2026
- Market cap
- $16.87M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
74.9%−1.6 pts over 5 years
Operating margin
-0.4%−3.4 pts over 5 years
Net margin
-14.1%−18.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -8.3% | -7.7% | -6.5% | -5.0% | |
| Gross profit | -11.5% | -8.1% | -6.9% | -5.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -1.5% | 23.5% | -897.3% | |
| Return on assets | -0.8% | 9.8% | -46.1% | |
| Current ratio | 1.69 | 1.33 | 1.10 | |
| Debt to equity | 0.01 | 0.00 | -0.53 | |
| Net debt to EBITDA | -14.09× | -3.43× | -5.16× | |
| Interest coverage | – | – | -1.0× | |
| Inventory turnover | 3.5× | 3.1× | 2.6× | |
| Capex to revenue | 1.3% | 0.6% | 1.3% | |
| Diluted shares | 3M | 2M | 2M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Mannatech generated $20.97M from operations and spent $17.95M on capital expenditure, dividends and share buybacks. 23% of that went back into the business.
Generated
$20.97M
Used
$17.95M
Capital expenditure$4.11M23%Dividends$6.63M37%Share buybacks$7.21M40%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-14.1%
×Asset turnover3.27×
×Equity multiplier19.48×
=Return on equity, FY2025-897.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -14.1% | 3.27× | 19.48× | -897.3% |
| FY2024 | 2.1% | 3.05× | 4.05× | 26.1% |
| FY2023 | -1.7% | 2.92× | 3.66× | -18.2% |
| FY2022 | -3.3% | 2.52× | 2.82× | -23.3% |
| FY2021 | 6.2% | 2.56× | 2.48× | 39.1% |
| FY2020 | 4.1% | 2.36× | 2.41× | 23.5% |
| FY2019 | 2.1% | 2.52× | 2.38× | 12.5% |
| FY2018 | -2.2% | 2.51× | 2.11× | -11.9% |
| FY2017 | -1.0% | 2.40× | 1.86× | -4.5% |
| FY2016 | -0.3% | 2.58× | 1.81× | -1.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$15.21M
- Cash generatingOperating cash flow above zero-$2.96M
- Return on assets improvedROA up on the prior year6.0% → -42.2%
- Earnings backed by cashOperating cash flow above net income-$2.96M vs -$15.21M
- Less leverageLong-term debt to assets fell8.0% → 9.2%
- Better liquidityCurrent ratio rose1.25 → 1.10
- No dilutionShare count did not rise2M → 2M
- Gross margin improvedGross margin up on the prior year77.60% → 74.94%
- More efficientAsset turnover rose2.86 → 3.00